This non-comparative, multicentre clinical trial included 43 patients whose acute or chronic wounds were treated with a new lipidocolloid dressing, Urgotul Duo, for at most 4 weeks, or until healing first occurred. The efficacy, tolerance and acceptability results obtained for this 'ready-for-use' dressing were similar to those reported for the Urgotul dressing in numerous previous clinical trials, and for all the different types of acute and chronic wounds. This well-tolerated new dressing greatly facilitates care operations in terms of execution (reduced use of supplementary gauzes for the secondary dressing) and duration (shorter nursing time), while improving patient comfort. This dressing is indicated for the local treatment of moderate exudative acute and chronic wounds in the granulation and epidermization phases.
C onventional greasy, neutral or impregnated dressings, have been used for many years to treat acute skin lesions (injuries, burns, etc.) and chronic wounds, in all types of aetiologies (Benbow, 2002) . This was further confirmed by the MAPP Observational Survey which involved 6000 patients in France (conducted by 658 GPs and specialists), which showed that conventional greasy dressings are very widely employed for the local management of acute and chronic wounds of different aetiologies (Meaume et al, 2004) : this survey reported that dressing changes were very often painful in more than 80% of care operations on acute and chronic wounds.
These greasy dressings have the drawback of often requiring daily changes, of inducing pain at dressing removal (Hermans, 1991; Hollinworth and Collier, 2000; Terrill and Varughese, 2000; Benbow, 2002) . S Meaume, Z Ourabah, P Charru, P Meyer, J Perez, A Sauvadet, S Bohbot When a particular dressing is chosen, the aim must be to create and maintain a local environment conducive to the healing process (Eaglstein and Falanga, 1997) , based on the concept of healing in a moist environment (Hinman and Maibach, 1963; Winter and Scales, 1963) .
Of the new dressing categories available today, the Urgotul lipido-colloid dressing has the recognized benefits of hydrocolloids (more widely spaced care operations), without the disadvantages of paraffin gauzes, as it can be changed without pain or trauma (Ma et al, 2006) .
Numerous clinical trials have shown this Urgotul lipidocolloid dressing to be effective, well tolerated and well accepted in the treatment of acute and chronic wounds (Meaume et al, 2002 (Meaume et al, , 2005 Benbow and Iosson, 2004; Smith et al, 2004; Ma et al, 2006) . Its excellent acceptance by both patients and nursing staff has also been reported in clinical trials conducted on the wounds encountered in paediatric practice (Letouze et al, 2004) and in the treatment of the skin lesions observed in congenital epidermolysis bullosa (Blanchet-Bardon and Bohbot, 2005) .
In a move to facilitate nursing care operations and improve patient comfort, a new ready-for-use dressing, Urgotul Duo ® (Figure 1) , has been developed. This dressing combines an Urgotul dressing with an absorbent neutral compress which renders the use of a secondary dressing (sterile compress or gauze) unnecessary.
This trial was, therefore, conducted to evaluate the efficacy, tolerance and acceptability of this new Urgotul This ready-for-use dressing may be employed without being covered by other compresses. It is, therefore particularly indicated for the management of moderate exudative acute or chronic wounds in their granulation and/or epidermization phases.
The dressing should be held in place with a bandage fixation and should be removed every two to three days, but may be left in place for longer if the clinician considers this appropriate in view of the clinical course.
It may be trimmed, without separating the polyester and viscose layers, for conformability to some difficult anatomical areas.
Clinical evaluation of Urgotul ® Duo Methods
The Urgotul Duo dressing was evaluated for its efficacy, tolerance and ease of use in an open label, non-controlled, multicentre (11 centres) clinical trial.
In all, 43 patients presenting with an acute or a chronic wound were included and followed up for, at most, four weeks, or until healing first occurred.
This clinical trial was approved by the Versailles Medical Ethics Committee (France) and was conducted in compliance with the rules of Good Clinical Practice in force and with the principles laid down in the Declaration of Helsinki.
Written, informed consent was obtained from all of the patients prior to inclusion in the trial.
Only patients hospitalized in geriatric institutions were included, thus ensuring that all the care operations conducted during the trial were documented. Acute or chronic wounds in the granulation phase, less than 100 cm 2 in size and not presenting any local sign of clinical infection were treated by the tested dressing.
The exclusion criteria included any patients who presented with any progressive neoplasic lesion, any known hypersensitivity to carboxymethylcellulose or who were receiving radiotherapy, chemotherapy or were taking immunosuppressive drugs.
The investigating physician performed a full clinical examination of the patient during the inclusion visit then photographed the wound and made a planimetric tracing of its outline (standard procedure provided by the sponsor). This medical evaluation was repeated on a weekly basis until healing, or for at most, four weeks.
This medical evaluation was combined with a nursing evaluation that was performed and documented at each wound care operation to provide qualitative information about wound evolution (condition of perilesional skin, odour, maceration, bleeding), patient comfort (pain on removal), and its practical aspects (ease of dressing application and removal).
A purely descriptive statistical analysis was performed on all the patients included in this trial. When considering the principal endpoint (evolution in wound surface area determined by planimetric measurement), the analysis of patients who withdrew before the fourth week of treatment took account of the last results available.
The results obtained for the secondary endpoints (tolerance, acceptability and comfort) were described Duo dressing in the treatment of acute or chronic wounds encountered in hospitals or in outpatient care settings.
Urgotul Duo: a new ready-for-use lipidocolloid wound dressing
Urgotul Duo is a new dressing composed of an Urgotul interface (polyester textile support impregnated with hydrocolloid particles and Vaseline in contact with the wound bed), and a 100% viscose, gas permeable and neutral absorbent (>500 g/m 2 ) compress. 
Results Patients
Forty-three patients were included in this clinical trial in 11 active investigating centres. Patient demographic characteristics at inclusion are reported in Table 1 . The vast majority of the patients were female (81.3%) and of an advanced age (hospitalized geriatric population): 27 patients (62.8%) presented an acute wound of traumatic origin and the other 16 patients (37.2%) with chronic wounds (9 leg ulcers, and 7 pressure ulcers). The characteristics of these different wounds are reported in Table 2 on the basis of their aetiology.
The 27 acute wounds had been present for an average of 5.3 ± 9.8 days, were primarily located on the lower limbs (51.9%) and were initially 13.4 ± 16.6 cm 2 in size. Most of these acute wounds prior to inclusion were covered by a contact layer, a paraffin gauze or a hydrocolloid dressing. This local treatment had been started on average 5.1 ± 3.9 days previously and was changed every 2 days for 58.9% of the wounds.
Nine of the 16 chronic wounds were leg ulcers. They had been present for an average of 6.5 ± 12.2 months and were on average 7.6 ± 4.6 cm 2 in size, with inflammatory perilesional skin in 44.4% of cases. These leg ulcers were most often treated with hydrocolloid or alginate dressings (66.7% of cases). Started on average 58.5 days previously, this previous local treatment was changed every 2 days for 87.5% of the wounds. On average, 2.4 compresses were being used in combination with the previous primary dressing in 50% of cases.
The other 7 chronic wounds were pressure ulcers (mostly located on heels). These were on average 8.5 ± 4.2 cm 2 in size and had been present for an average of 11.7 ± 21.9 weeks, with healthy perilesional skin in 71.4% of cases.
These pressure ulcers were previously treated with hydrocolloid dressings in 42.9% of cases and with alginate dressings in 28.5% of cases. This local treatment prior to inclusion had been used for an average of 25.8 days, with dressings changed every 2 days. On average, 2.7 compresses were being used in combination with this previous local treatment in more than 50% of cases (57.1%).
Drop-out
Three of the 43 patients (7%) withdrew from the trial before the 4th week of follow-up for reasons other than wound healing: two patients experienced an intercurrent event (transfer to another ward rendered the continuation of follow-up impossible) and one patient in the pressure ulcers group presented a local adverse event (secondary infection of the wound on day 6, considered by the investigating physician as not related to the study treatment).
In addition, 17 of the 43 patients showed healing before the 4th week of follow-up (15 patients in the acute wounds group and 2 in the chronic wounds group).
Healing rate
In all, 23 wounds (53.4%) had healed by the end of the 4-week follow-up period. These comprised 20 acute wounds that healed in a mean of 17.4 ± 8.1 days and three chronic wounds (two leg ulcers in a mean of 25 days and one pressure ulcer after 21 days of treatment).
When considering the reduction in wound surface area, it was seen that wound size by the end of the treatment with the study dressing had been reduced by 93.7%, 76.1% and 74.8% for acute wounds, leg ulcers and pressure ulcers, respectively. This reduction in mean surface area over time is presented in Figure 2 .
Dressing changes
In all, 396 care operations were documented in the course of the trial on the three wound groups: these corresponded to 980 cumulated days of treatment (563 days for acute wounds, 255 for leg ulcers and 162 for pressure ulcers).
Dressings were changed, on average, every 2.5 to 2.8 days, but in certain cases, nursing staff were able to leave the dressings in place for up to 8 days. 
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Supplementary gauzes were combined with the study dressing in 2% of care operations on acute wounds and in 14% and 21% of cases for chronic leg ulcers and pressure ulcers, respectively. In these cases, on average between 1.8 and 2.2 gauzes were used, depending on wound type.
Nurses considered dressing application and changing times to be shorter in 75% of cases (all care operations) and considered operations to be facilitated in 84% of cases (all care operations). These results are presented in more detail in Table 3 .
The results considering the acceptability of the dressing are presented in detail in Table 4 . Study dressing application and removal was considered to be very easy or easy for the vast majority of care operations performed. Dressing conformability to the bed of the wound was considered to be very good in nearly 80% of the care operations performed on acute wounds and leg ulcers, but the score was lower for pressure ulcers (58.5%). If all wounds are considered together, it can be seen that in about 90% of the care operations, no pain and no odour were reported. Minimal study dressing adhesion was noted in less than 20% of all dressing removals documented.
Local tolerability
Two local adverse events were reported in the course of this clinical trial: one in the acute wounds group and one in the pressure ulcer group.
A patient in the acute wounds group experienced a superficial lesion (phlyctena) some distance from the treated wound on day 21 of the follow-up period: this resolved spontaneously without any necessity to suspend study treatment (the investigator did not exclude the possibility that the event was treatment-related).
A patient in the pressure ulcers group experienced a secondary infection of the wound on day 6 of the follow-up period. This caused the investigating physician to definitively discontinue study treatment (although this event was not considered to be related to the study dressing).
The investigators reported that the condition of perilesional skin improved during the trial: by the end of the treatment, this was considered to be 'healthy' in 83% of patients showing acute wounds, 57% showing leg ulcers and 100% showing pressure ulcers (vs 55%, 44% and 71% at the start of the trial).
The inflammatory aspect of this perilesional skin disappeared entirely in patients presenting with acute wounds and pressure ulcers, but remained present in 28% of cases in the leg ulcers group (vs 44% at inclusion in this group).
Discussion
The Urgotul lipido-colloid wound dressing launched in 2000 was a veritable alternative to both conventional and modern dressings and is characterized by its atraumatic and painless removal (Benbow and Iosson, 2004; Letouze et al, 2004; Ma et al, 2006) and its promotion of the healing process (Bernard et al, 2004; Meaume et al, 2005) .
Moves to optimize nursing care operations and improve patient comfort led to the development of the Urgotul Duo dressing. This corresponds to an 'all-in-one', readyfor-use dressing, as it combines an Urgotul dressing with an absorbent neutral compress which is equivalent to two gauzes in terms of absorption.
Since this clinical trial was non-controlled, only indirect comparisons can be made with data published in the literature, most notably results concerning the Urgotul dressing. Thus, the physicians and nurses who followed the wounds treated in this trial, reported that the efficacy of this new dressing, as evaluated by wound size reduction, was at least equivalent to that of Urgotul (average reduction of 93%, 76% and 74% in the size of acute wounds, leg ulcers and pressure ulcers, respectively, vs 76%, 63% and 44% reported for the Urgotul dressing on wounds with similar characteristics (Meaume et al, 2002) .
This new dressing was well accepted by nurses and well tolerated by patients in the course of this trial, in the same manner as observed in paediatric practice (Letouze et al, 2004) , on lesions of epidermolysis bullosa (BlanchetBardon and Bohbot, 2005) and on wounds both acute (Burton, 2004) and chronic (Muenter, 2003; Tormo et al, 2003; Meaume et al, 2005; Rueda Lopez et al, 2005) . In addition to these results relative to the lipido-colloid technology, this clinical trial also showed that this new, ready-for-use dressing facilitates nursing care operations, given that the combination of an absorbent compress and an Urgotul dressing in 91% of cases meant that supplementary gauzes were unnecessary when preparing the secondary dressing. In addition, the Urgotul Duo dressing was changed every 2.5 to 2.8 days, i.e. the same frequency observed at inclusion with other modern dressings which were often covered by supplementary gauzes.
Nursing staff also considered that use of the Urgotul Duo dressing reduced dressing application and changing times in 84% of documented care operations. 
Conclusion
The use of fewer compresses to prepare the secondary dressing, coupled with faster dressing changes and fewer handling operations, all converge to produce optimized nursing care and greater comfort for both the patient and healthcare professionals.
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